{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.4","upperLimit":"27.1","value":"18.3"},{"groupId":"OG001","lowerLimit":"7.0","upperLimit":"28.6","value":"15.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"51"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: Disappearance of all target and non-target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target and non-target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded central imaging vendor. Participants with missing data were considered non-responders. The percentage of participants who experienced a CR or PR per RECIST 1.1 is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with previously systemically treated HCC received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.","id":"OG000","title":"Cohort 1: HCC-Prior Systemic Therapy With Sorafenib"},{"description":"Participants with HCC who had not received treatment for systemic disease received a pembrolizumab 200 mg IV infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stopped pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stopped after receiving 35 trial treatments were eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they met the criteria for re-treatment.","id":"OG001","title":"Cohort 2: HCC-Systemic Therapy Naïve"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of study treatment during the first course of therapy.","reportingStatus":"POSTED","timeFrame":"Up to approximately 34 months for Cohort 1 and up to approximately 28 months for Cohort 2","title":"Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}